image_pdfimage_print
11 08, 2023

SB 51

The Cost-Sharing Contributions for Prescriptions would prohibit discrimination against entities participating in the federal 340B drug pricing program. It states that pharmacy benefit managers and third parties cannot discriminate against entities that participate in the 340B program by: Reimbursing a covered entity less than it would an entity not covered by the 340B program,  Assessing covered entities fees or other assessments different from non-covered entities,  preventing or interfering with a patient’s right to use a 340B program drug from a covered entity,  Imposing different requirements for covered vs. non-covered entities, including: [...]

SB 51
11 08, 2023

SB 498

Senate Bill 498 would amend the Pharmacy Benefits Manager Regulation Act to expand the maximum-allowable-cost process from generic pharmaceuticals to all pharmaceuticals and to increase the amount of information provided on the maximum-allowable-cost list. Additionally, the bill would require pharmacy benefits managers to set reimbursement rates no lower than a pharmacy is able to purchase the drug from their wholesaler. Finally, the bill would require pharmacy benefits managers to allow any pharmacy access to its preferred pharmacy network and prohibits a manager from restricting an individual’s choice in pharmacy.

SB 498
2 05, 2023

HB 400

State-administered Health Coverage Plan. An Act relating to health care, requiring a study on the feasibility of creating and implementing a state-administered health coverage plan.

HB 400
25 04, 2023

HB 385

Health Practitioner Nonsolicitation. A nonsolicitation provision in an agreement, which provision restricts the right of a health care practitioner to solicit patients or employees of the party seeking to enforce the agreement, shall be unenforceable upon the termination of: (1) the agreement; (2) a renewal or extension of the agreement; or (3) a health care practitioner's employment with a party seeking to enforce the agreement."

HB 385
15 03, 2023

Healthcare Merger Watch Q1 2023: Nationwide Cross-Market Merger Mania

In this first healthcare merger watch of 2023, we highlight some consolidation activities from the first quarter in the healthcare industry. In a trend that has continued in recent years, healthcare entities in the latest proposed and pending deals are increasingly exploring consolidation in new and innovative ways, across different geographic regions and involving different healthcare players in the industry. Even though federal and state antitrust enforcers often successfully challenge traditional, horizontal mergers and acquisitions, transactions involving cross-market consolidation are typically not challenged due to less straightforward legal and economic theories in proving potential [...]

Healthcare Merger Watch Q1 2023: Nationwide Cross-Market Merger Mania